TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.

Xuan Ying Poh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.